Présentation de l'entreprise
Nexentis Technologies Inc. operates within the basic materials sector, specifically focusing on the agricultural inputs industry, where its business model centers on developing and operating an AI and data-driven computational biotech platform. The company's strategic focus areas include mitochondrial biology, precision oncology, and inflammatory metabolic diseases, leveraging a proprietary MITOLINE discovery engine and structural biology capabilities. The entity currently maintains a market capitalization of $3.32 million and employs a workforce of 3 individuals, while reporting a trailing twelve-month revenue of $209,000. These financial metrics indicate that Nexentis Technologies Inc. functions as a micro-cap enterprise with minimal revenue generation relative to its market valuation, suggesting a position typical of early-stage biotechnology firms that prioritize research and development over immediate profitability.
Santé financière
The company reported a revenue of $209,000 over the trailing twelve months, yet it incurred a net income of -$6,942,000 and an EBITDA of -$6,024,000, revealing a significant divergence between top-line sales and bottom-line profitability. This substantial gap between revenue and net income highlights a cost structure characterized by heavy expenditures on research and development, operational overhead, or other non-operating expenses that consume the majority of generated cash flow. The free cash flow stands at -$3,829,648, indicating that the company is currently burning cash at a rate that exceeds its operational cash generation, which limits its immediate financial flexibility and reliance on external capital sources. Margin analysis shows a gross margin of 64.6%, suggesting efficient production or sourcing of direct costs, contrasted sharply by an operating margin of -66300.0% and a profit margin of 0.0%, which reflect severe operational inefficiencies or significant one-time charges impacting the bottom line. In terms of leverage, Nexentis holds $6.28 million in cash against $1.14 million in debt, resulting in a debt-to-equity ratio of 13.08, which presents a mixed picture of strong liquidity reserves offset by a high leverage ratio relative to equity. The current ratio of 4.21 indicates that the company possesses ample short-term assets to cover its liabilities, suggesting robust short-term liquidity despite the cash burn rate. Return on equity is recorded at -101.6% and return on assets at -44.8%, metrics that demonstrate management has not yet achieved profitability and is currently eroding shareholder and asset value through negative returns.
Évaluation de la valorisation
Trailing P/E and forward P/E ratios are both listed as N/A, implying that the absence of positive earnings prevents the calculation of these traditional multiples and signals that earnings are not currently growing or are negative. The price-to-book ratio is 0.10, indicating that the market values the company at a fraction of its book value, which often occurs when assets are undervalued or when the business model relies on intangible assets not fully captured on the balance sheet. The price-to-sales ratio stands at 15.90, while the EV/EBITDA is 0.60, suggesting that the market is willing to pay a significant premium relative to sales despite the lack of earnings, a common valuation characteristic for speculative biotech firms awaiting clinical milestones. The stock has a 52-week high of $29.40 and a 52-week low of $0.64, meaning the current market price trades significantly below the recent peak, reflecting a prolonged period of underperformance or market skepticism regarding its near-term prospects. With a beta of 1.81, the stock exhibits high volatility, moving nearly twice as much as the broader market, which increases the risk profile for investors sensitive to market fluctuations.
Growth & Income
Revenue growth year-over-year is -77.8%, while earnings growth year-over-year is N/A, indicating that the company is shrinking in terms of sales and has no positive earnings growth trajectory to analyze. The decline in revenue suggests a contraction in business operations or a failure to commercialize its biotech platform effectively in the current fiscal period. As a non-dividend payer, Nexentis Technologies Inc. does not distribute a dividend yield or maintain a payout ratio, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company retains all its earnings, or rather its cash reserves, to fund its research initiatives rather than providing income to shareholders. The overall growth and income profile is characterized by negative revenue expansion and a complete lack of dividend distribution, positioning the equity as a pure speculation on future technological breakthroughs rather than a source of financial stability or income.